The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Clinical Implications of Basic Research
PreviousPrevious
Volume 356:79-81 January 4, 2007 Number 1
NextNext

p53 and Tumor Suppression
Terry Van Dyke, Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
The p53 tumor-suppressor protein is dysfunctional in most human cancers. Even when p53 is not itself mutant, its regulators — such as p14ARF — are often altered. Moreover, for any given cancer type, p53 dysfunction generally correlates with poor treatment response and poor prognosis, so restoration of p53 function is a potential avenue for therapeutic development.

The p53 protein is a key responder to a variety of stresses, including DNA damage, hypoxia, and cell-cycle aberrations. The specific molecular pathways that activate p53 depend on the nature of the stress and the cell type. These, in turn, determine the specific downstream . . . [Full Text of this Article]


Source Information

From the Department of Genetics and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.